Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Drug Insights
4 min read
Desonide: Detailed Review of its Transformative R&D Success, Mechanism of Action
13 September 2023
This article summarized the latest R&D progress of Desonide, the Mechanism of Action for Desonide, and the drug target R&D trends for Desonide.
Latest Hotspot
4 min read
Seladelpar from CymaBay Reaches Significant Statistical Levels for primary and key Secondary endpoints in the RESPONSE Phase 3 Trial
13 September 2023
Biotech firm CymaBay Therapeutics, Inc. revealed positive Phase 3 trial outcomes for seladelpar, a novel treatment for liver and chronic diseases, including primary biliary cholangitis. Meeting all primary and key secondary endpoints.
Drug Insights
4 min read
Clindamycin Phosphate Unveiled: A Detailed Overview of its Revolutionary R&D Breakthroughs, Mechanisms of Action, and Drug Target
13 September 2023
This article summarized the latest R&D progress of Clindamycin Phosphate, the Mechanism of Action for Clindamycin Phosphate, and the drug target R&D trends for Clindamycin Phosphate.
Valuable Targets
7 min read
JAK1 Inhibitor - A rising star of small molecule targeted drugs in the field of autoimmunity
13 September 2023
In autoimmune diseases, JAK inhibitors can mediate immune suppression and inhibit the increase of serum pro-inflammatory cytokines.
Drug Insights
4 min read
A Comprehensive Review of Cefuroxime Axetil's R&D Innovations and Drug Target Mechanism
13 September 2023
This article summarized the latest R&D progress of Cefuroxime Axetil, the Mechanism of Action for Cefuroxime Axetil, and the drug target R&D trends for Cefuroxime Axetil.
Latest Hotspot
3 min read
Adrenomed presents novel results for their precision medicine therapy with enibarcimab for septic shock
13 September 2023
Adrenomed AG has disclosed recent discoveries regarding the biomarker-directed therapy of septic shock with enibarcimab.
Drug Insights
4 min read
Pharmaceutical Insights: Ceftazidime's R&D Progress and its Mechanism of Action on Drug Target
13 September 2023
This article summarized the latest R&D progress of Ceftazidime, the Mechanism of Action for Ceftazidime, and the drug target R&D trends for Ceftazidime.
Valuable Targets
7 min read
The Research and Development Boom is Unstoppable-KRAS G12D Inhibitors
12 September 2023
KRAS G12D differs from KRAS G12C only in the type of amino acid mutation on the same codon.
Drug Insights
4 min read
Exploring Cefadroxil's Revolutionary R&D Successes and its Mechanism of Action on Drug Target
12 September 2023
This article summarized the latest R&D progress of Cefadroxil, the Mechanism of Action for Cefadroxil, and the drug target R&D trends for Cefadroxil.
Latest Hotspot
4 min read
Clinical trials starts for DS-3939, aimed at treating a variety of complex Advanced Solid Cancers
12 September 2023
Daiichi Sankyo has declared that the first patient has been dosed in a first-in-human Phase 1/2 examination evaluating DS-3939.
Valuable Targets
6 min read
Observations on the Use of CB1 Antagonists in Disease Treatment
12 September 2023
The Cannabinoid receptor 1 (CB1), as one of the most classic receptors of the Endocannabinoid system (ECS), is a G protein-coupled membrane receptor.
Drug Insights
4 min read
Deep Scientific Insights on Cefaclor's R&D Progress, Mechanism of Action, and Drug Target
12 September 2023
This article summarized the latest R&D progress of Cefaclor, the Mechanism of Action for Cefaclor, and the drug target R&D trends for Cefaclor.